Skip to main content
SpringerLink
Log in

Prädiktive Biomarker beim Prostatakarzinom

Androgenrezeptor-Spleißvariante AR-V7: Implikationen für die Praxis

  • Fortbildung
  • Published:
Uro-News Aims and scope

Mittlerweile stehen verschiedene Therapeutika zur Behandlung des metastasierten kastrationsresistenten Prostatakarzinoms zur Verfügung. Allen gemeinsam ist, dass das Ansprechen des Patienten und auch die Dauer des Ansprechens auf die verschiedenen Therapeutika, bisher nicht vorausgesagt werden kann. Ein geeigneter prädiktiver Biomarker, der dieses Problem löst, wird gesucht. Dabei wird auch die Androgenrezeptor-Spleißvariante AR-V7 als Option gehandelt.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. Cutress ML, Whitaker HC, Mills IG, Stewart M, Neal DE. Structural basis for the nuclear import of the human androgen receptor. J Cell Sci. 2008; 121: 957–68.

    Article  CAS  PubMed  Google Scholar 

  2. Yu Z, Chen S, Sowalsky AG, et al. Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer. Clin Cancer Res. 2014;20: 1590–600.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA, Dehm SM. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res. 2013; 73: 483–9.

    Article  CAS  PubMed  Google Scholar 

  4. Hu R, Lu C, Mostaghel EA, Yegnasubramanian S, Gurel M, Tannahill C, et al. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res. 2012; 72: 3457–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res. 2008; 68: 5469–77.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Xu D, Zhan Y, Qi Y, Cao B, Bai S, Xu W, et al. Androgen Receptor Splice Variants Dimerize to Transactivate Target Genes. Cancer Res. 2015; 75: 3663–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 2008; 26: 3213–21.

    Article  PubMed  Google Scholar 

  8. Armstrong AJ, Marengo MS, Oltean S, Kemeny G, Bitting RL, Turnbull JD, et al. Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Mol Cancer Res. 2011; 9: 997–1007.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Pantel K, Speicher M. The biology of circulating tumor cells. Oncogene. 2016; 35: 1216–24.

    Article  CAS  PubMed  Google Scholar 

  10. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012; 2012: 883–92.

    Article  Google Scholar 

  11. Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014; 371: 1028–38.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Steinestel J, Luedeke M, Arndt A, Schnoeller TJ, Lennerz JK, Wurm C, et al. Detecting predictive androgen receptor modifications in circulating prostate cancer cells. Oncotarget. 2015 [Epub ahead of print].

  13. Steinestel J, Schrader AJ, Luedeke M. Resistance to androgen-pathway drugs in prostate cancer. N Engl J Med. 2014; 371: 2234.

    PubMed  Google Scholar 

  14. Zhu ML, Horbinski CM, Garzotto M, Qian DZ, Beer TM, Kyprianou N. Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res. 2010; 70: 7992.8002.

  15. Thadani-Mulero M, Portella L, Sun S, Sung M, Matov A, Vessella RL, et al. Androgen receptor splice variants determine taxane sensitivity in prostate cancer. Cancer Res. 2014; 74: 2270–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Nakazawa M, et al. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer. JAMA oncology. 2015; 1: 582–91.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Onstenk W, Sieuwerts AM, Kraan J, Van M, Nieuweboer AJ, Mathijssen RH, et al. Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells. Eur Urol. 2015; 68(6): 939–45.

    Article  CAS  PubMed  Google Scholar 

  18. Scher HI, Lu D, Schreiber NA, Louw J, Graf RP, Vargas HA, et al. Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer. JAMA oncology. 2016; 2: 1441–9.

    Article  PubMed  PubMed Central  Google Scholar 

  19. McShane LM. In pursuit of greater reproducibility and credibility of early clinical biomarker research. Clin Transl Sci. 2017; 10(2): 58–60.

    Article  CAS  PubMed  Google Scholar 

  20. Bernemann C, Schnoeller TJ, Luedeke M, Steinestel K, Boegemann M, Schrader AJ, et al. Expression of AR-V7 in circulating tumour cells does not preclude response to next generation androgen deprivation therapy in patients with castration resistant prostate cancer. Eur Urol. 2017; 71: 1–3.

    Article  CAS  PubMed  Google Scholar 

  21. Antonarakis E, Lu C, Luber B, Wang H, Chen Y, Zhu Y. AR-V7 and efficacy of abiraterone (Abi) and enzalutamide (Enza) in castration-resistant prostate cancer (CRPC): expanded analysis of the Johns Hopkins cohort. J Clin Oncol. 2016; 34(suppl; abstr 5012).

  22. Steinestel J, Bernemann C, Schrader AJ, Lennerz JK. Reply from Authors re: Emmanuel S. Antonarakis, Howard I. Scher. Do Patients With AR-V7-Positive Prostate Cancer Benefit from Novel Hormonal Therapies? It All Depends on Definitions. Eur Urol. 2017; 71(1): 4.6: Unsplicing a Conflict.

  23. Markowski MC, Frick KD, Eshleman JR, Luo J, Antonarakis ES. Cost-Savings Analysis of AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer Eligible for Treatment With Abiraterone or Enzalutamide. Prostate. 2016; 76: 1484–90.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Urologie, Universitätsklinikum Münster, Albert-Schweitzer Campus 1, GB A1, 48149, Münster, Deutschland

    Julie Steinestel

Authors
  1. Julie Steinestel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Julie Steinestel.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Steinestel, J. Androgenrezeptor-Spleißvariante AR-V7: Implikationen für die Praxis. Uro-News 21, 22–26 (2017). https://doi.org/10.1007/s00092-017-1482-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00092-017-1482-x

Search

Navigation